Zenagamtide Achieves 14.6% Weight Loss as Wegovy Tablets Hit 3 Million Prescriptions
NVO•Novo Nordisk’s Phase 3 CagriSema trial showed significant HbA1c and weight loss reductions while Phase 2 zenagamtide achieved up to 14.6% body-weight reduction. Wegovy tablets topped 3 million U.S. prescriptions in five months with over 80% of users new to GLP-1 therapy and early uptake of the 7.2 mg Wegovy HD shot strong.
1. CagriSema Phase 3 Results
Novo Nordisk presented Phase 3 data for CagriSema, an amylin analog combined with a GLP-1 receptor agonist, demonstrating significant reductions in HbA1c and substantial weight-loss improvements versus comparator arms.
2. Zenagamtide Phase 2 Data
Phase 2 results for zenagamtide revealed dose-dependent benefits with up to 14.6% mean body-weight reduction, underscoring its potential as a next-generation obesity therapy.
3. Wegovy Tablet Prescriptions
Wegovy oral tablets exceeded 3 million U.S. prescriptions in five months, achieving a fill rate of one prescription every five seconds and attracting over 80% of patients new to GLP-1 treatment.
4. Wegovy HD and Global Expansion
The 7.2 mg Wegovy HD weekly injection has shown strong early uptake as Novo Nordisk launched the pill in the UAE and plans further international rollouts, supported by pricing from $25 monthly and a $50 Medicare Bridge copay.
